Φορτώνει......
Antiangiogenic therapy in breast cancer
Based on a strong rationale for anti-VEGF (vascular endothelial growth factor) treatment in breast cancer and promising preclinical data, great hopes have been placed on the anti-VEGF antibody bevacizumab. Clinical trials, however, reported conflicting results. In metastatic human epidermal growth f...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Memo |
|---|---|
| Κύριοι συγγραφείς: | , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Springer Vienna
2017
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5725520/ https://ncbi.nlm.nih.gov/pubmed/29250196 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12254-017-0362-0 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|